|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristic** | **c-TREnd subpopulation (N=46)** | **Original TREnd population (N=115)** | **p-value** |
| Age (range) | 64 (39-82) | 65 (38-82) | 0.7 |
| ECOG performance status  0  1  2 | 37 (81%)  8 (17%)  1 (2%) | 88 (76%)  25 (22%)  2 (2%) | 0.9 |
| Sites of metastases  Visceral  Bone-only  Other non-visceral | 33 (72%)  5 (11%)  8 (17%) | 87 (76%)  9 (8%)  19 (16%) | 0.8 |
| Number of prior lines of endocrine therapy received for advanced disease  0 lines  1 line  2 lines  3 lines | 0  30 (65%)  16 (35%)  0 | 1 (1%)\*  79 (68%)  33 (29%)  2 (2%)\* | 0.8 |
| Duration of most recent endocrine therapy received  No prior endocrine therapy   6 months  >6 months | 0  8 (17%)  38 (83%) | 1 (1%)\*  30 (26%)  84 (73%) | 0.5 |
| Endocrine therapy most recently received prior to enrolment  No prior endocrine therapy  Aromatase inhibitor  Fulvestrant | 0  27 (59%)  19 (41%) | 1 (1%)\*  63 (55%)  51 (44%) | 0.8 |
| Receipt of prior chemotherapy for advanced disease?  Yes  No | 9 (20%)  37 (80%) | 35 (30%)  80 (70%) | 0.2 |
| Total number of prior lines of systemic therapy for advanced disease  0 lines  1 line  2 lines  3 lines  4 lines | 0  25 (54%)  17 (37%)  4 (9%)  0 | 1 (1%)\*  55 (48%)  47 (41%)  11 (9%)  1 (1%)\* | 0.9 |
| Clinical benefit observed on trial?  Yes  No | 28 (61%)  18 (39%) | 66 (57%)  49 (43%) | 0.7 |

**Supplementary Table 1**: Baseline characteristics of studied c-TREnd biomarker population – including all patients with at least one sample available for analysis at any timepoint(s), compared to the overall original TREnd cohort. Fisher exact test was used to calculate p-values.

\*Denotes patients included in intention-to-treat population of TREnd, despite breach of eligibility criteria (discovered post-enrolment).